Anavex Life Sciences Corp. (NASDAQ:AVXL) Q2 2023 Earnings Conference Call May 9, 2023 8:30 AM ET
Company Participants
Clint Tomlinson - Investor Relations
Christopher Missling - President and Chief Executive Officer
Sandra Boenisch - Principal Financial Officer
Conference Call Participants
Soumit Roy - Jones Research
Clint Tomlinson
Good morning. Welcome to the Anavex Life Sciences Fiscal 2023 Second Quarter Conference Call. My name is Clint Tomlinson, and I will be your host for today's call. At this time, all participants are in a listen-only mode. Later, we'll conduct a question-and-answer session. And during this session, if you would like to ask a question, please use the Q&A box or raise your hand. Please note, this conference is being recorded. The call will be available for replay on Anavex's website at www.anavex.com.
With us today, Dr. Christopher Missling, President and Chief Executive Officer; and Sandra Boenisch, Principal Financial Officer.
Before we begin, please note that during this conference call, the company will make some projections and forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. We encourage you to review the company's filings with the SEC. And this includes, without limitation, the company's Forms 10-K and 10-Q, which identify specific factors that may cause actual events or results to differ materially from those described in these forward-looking statements. These factors may include, without limitation, risk inherent in the development and/or commercialization of potential products, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital and maintenance of intellectual property rights.
And with that, I would like to turn the call over to Dr. Missling.
Christopher Missling
Thank you, Clint, and good morning, everyone. Thank you for being with us today to review our most recently reported financial results and to provide our quarterly business update.
Recent positive clinical study results and FDA approvals through the Accelerated Approval Pathway are positive for the Alzheimer's disease community, especially for patients, families and caregivers who fight everyday against this devastating disease.
We look forward to presenting, including in a scientific journal once available, the complete dataset of the Phase 2b/3 Alzheimer's disease trial of ANAVEX2-73, blarcamesine, a convenient once-daily oral small-molecule activator of the upstream sigma-1 receptor, involved in restoring neural cell homeostasis and promoting neuroplasticity, which might be at the forefront of patient-centric, next-generation biomarker-guided precision medicine Alzheimer's disease treatments.